lipostat 20mg tablets
bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 20 mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet: reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation
lipostat 40mg tablets
bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 40mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet; reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation.
lipostat 10mg tablets
bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 10mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet; reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation.
perfalgan 1g/100ml solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - paracetamol - solution for infusion - 10mg/1ml
perfalgan 500mg/50ml solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - paracetamol - solution for infusion - 10mg/1ml
reyataz 150mg capsules
bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate - capsule - 150mg
reyataz 200mg capsules
bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate - capsule - 200mg
baraclude 0.5mg tablets
bristol-myers squibb pharmaceuticals ltd - entecavir monohydrate - tablet - 500microgram
baraclude 1mg tablets
bristol-myers squibb pharmaceuticals ltd - entecavir monohydrate - tablet - 1mg
sprycel 20mg tablets
bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 20mg